Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HEXKIN

Financiado

Cerrado

Healing Exosomes for sKIN

Currently, there are about 50 million reported cases globally of patients suffering from hard-to-close wounds, which constitute a severe cost burden to the global healthcare systems. Considering that for these patients up to 70% o... ver más

31/03/2017

EXOGENUS THERAPEUT...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

EXOGENUS THERAPEUTICS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-03-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EXOGENUS THERAPEUTICS

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2014-53763-P ACTIVIDAD HIPOXIMIMETICA DE NUEVOS DERIVADOS DEL CANNABIDIOL... 145K€ Cerrado

FORCE REPAIR smart and multiFunctional 3D printable prO Regenerative biol... 5M€ Cerrado

VascColl Temporally controlled delivery of vascular therapeutics from... 188K€ Cerrado

SAF2017-83734-R REPARACION CARDIACA UTILIZANDO INGENIERIA TISULAR Y/O EXOSOM... 127K€ Cerrado

JCI-2011-09030 Ingeniería tisular de epitelios, equivalentes dermo-epidérmi... 96K€ Cerrado

Everfill Improving the Quality of Life of Millions through the Revolu... 71K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2016-11-30
Fecha Fin: 2017-03-31

Líder del proyecto

EXOGENUS THERAPEUTICS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently, there are about 50 million reported cases globally of patients suffering from hard-to-close wounds, which constitute a severe cost burden to the global healthcare systems. Considering that for these patients up to 70% of the wounds may not heal with standard care, there is a high demand for new solutions with better efficacy for the treatment of wounds. Cell therapies have emerged as promising therapeutic strategies to solve the problem of chronic wounds, but the limited engraftment and survival of the cells have restricted their efficacy in late stages of human trials. Exogenus is a spin-out company dedicated to develop a new therapeutic tool for the treatment of chronic wounds – Exo-Wound - which the company now seeks to clinically validate for diabetic ulcers. Exo-Wound is based on factors secreted by Umbilical Cord Blood (UCB) cells which accelerate the healing of skin wounds through promotion of vascularisation and stimulation of skin growth. Results from the animal models reveal important improvements in the healing capacity, treatment duration and biocompatibility when compared to competition. Nevertheless, in order to secure swift product development and successful commercialisation Exogenus is in need of partnerships and capital to overcome the classic Valley of death gap. We believe the SME instrument is the ideal funding vehicle for us to establish Exo-Wound clinical validation and undertake the necessary activities to demonstrate safety and efficacy of the product in humans, and eventually achieve successful, global commercialization. The project will contribute to place Exogenus in a competitive position within the advanced wound care market and assist Europe in maintaining its competitive position in the fast growing segment of active therapies. The accomplishment of the project objectives will lead to a significant business opportunity for Exogenus, and generate revenues of around €30 million, five years after market entrance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores